Dexavetaderm

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dexavetaderm

Quick Facts

Property Description
Active Ingredients Dexamethasone, Neomycin
Form Solution, Suspension, Cream, or Ointment
Pharmacological Class Combined Anti-inflammatory and Anti-infective Agent
General Purpose Simultaneous relief of inflammation and treatment of bacterial infection
Origin Synthetic (Corticosteroid and Antibiotic components)

What is the Composition and Class of Dexavetaderm?

Dexavetaderm is a prescription combination therapy defined by its dual active ingredients: the potent synthetic glucocorticoid Dexamethasone and the aminoglycoside antibiotic Neomycin. The preparation is formally classified as a combined anti-inflammatory and anti-infective agent, a categorization well-established in clinical practice. The use of this specific corticosteroid-antibiotic pairing is clinically recognized for its broad utility in localized therapies.

This formulation is an example of a preparation widely used where both inflammatory symptoms and a confirmed or suspected bacterial presence are factors. Dexamethasone is a highly potent synthetic corticosteroid with significant anti-inflammatory properties, which function to reduce local immune responses. Concurrently, the Neomycin component functions as an aminoglycoside antibiotic, working to eliminate susceptible bacteria by inhibiting their vital protein synthesis.

The Dual Purpose of this Corticosteroid and Antibiotic Combination

The general purpose of this combination medicine is to provide relief from the symptoms of inflammation where there is a confirmed presence of, or a high risk for, a bacterial infection. The preparation achieves this by utilizing the anti-inflammatory action of Dexamethasone, which quickly suppresses symptoms like swelling and itching, coupled with the potent anti-infective action of Neomycin. This dual mechanism is the central principle of its design.

The medicine is typically prepared for topical use, meaning it is intended for application directly to the affected site, such as the skin, the eye (ophthalmic), or the ear (otic), which localizes its effects. It is available in various pharmaceutical preparations, including a sterile solution, a suspension, a cream, or an ointment, allowing the form to be selected based on the specific anatomical area and the nature of the condition being managed.

Regulatory References

  1. Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension/Ointment (DailyMed)

What side effects are possible with Dexavetaderm?

Possible side effects and safety information

The safety profile of Dexavetaderm, a combination of Dexamethasone and Neomycin, is formally defined by effects categorized across several System-Organ Classes (SOC), as documented in official regulatory labeling.

Common Adverse Reactions and Systemic Concerns

Adverse reactions that are frequently observed include localized effects such as stinging, burning, or discomfort at the application site. For ophthalmic preparations, a transient elevation of Intraocular Pressure (IOP) is classified as common. The overall safety pattern is significantly influenced by the potential for systemic absorption, particularly with the Neomycin component, which is associated with risks of Nephrotoxicity and Irreversible Ototoxicity following extensive exposure.

System-Organ Class Key Adverse Reactions (Label Documented)
Eye Disorders IOP elevation, Cataracts, Glaucoma
Ear Disorders Ototoxicity (risk related to Neomycin)
Endocrine Disorders Hypercortisolism, Adrenal Suppression
Skin Disorders Allergic Contact Dermatitis

Duration-Related and Serious Adverse Reactions

The development of serious adverse reactions, including Glaucoma and Posterior Subcapsular Cataracts, is officially associated with prolonged use of the corticosteroid component. The label also documents the rare risk of Anaphylactic Shock linked to Neomycin exposure.

Population and Use Restrictions

Regulatory documents highlight that pediatric patients may face an increased risk of systemic effects, such as growth suppression, due to heightened absorption. Furthermore, use is contraindicated in the presence of certain non-bacterial infections or a known hypersensitivity to the ingredients. For otic use, the preparation is formally restricted if the tympanic membrane is perforated, due to the risk of inner ear damage.

Overdose and Emergency Response

Overdose and when to seek help

Overdose scenarios for this combination product are primarily associated with the systemic absorption of its active ingredients, typically following prolonged or extensive application beyond labeled instructions.

Documented Manifestations and Severe Outcomes: The corticosteroid component, Dexamethasone, when absorbed systemically in excess, may lead to documented clinical signs of exogenous hyperadrenocorticism and symptoms of adrenal suppression. The Neomycin antibiotic component, if absorbed systemically, carries the specific regulatory risk of neurotoxicity and nephrotoxicity, with the potential for severe outcomes, including permanent sensorineural hearing loss ( ototoxicity). Serious or life-threatening events, such as anaphylaxis or respiratory compromise, are explicitly noted as potential complications.

Population Considerations and Monitoring: Regulatory guidance identifies specific populations at increased risk from systemic absorption. Children, elderly individuals, and patients with impaired renal function are noted to have a greater risk for Neomycin-induced toxicities. Following suspected systemic exposure, official guidance includes requirements for symptomatic and supportive treatment and mandated monitoring of both renal function and the eighth cranial nerve (audiometric testing).

When to Seek Immediate Medical Help: The official labeling states that immediate medical attention is required for the onset of generalized allergic reactions or any symptom indicating a life-threatening scenario, such as difficulty breathing. Contacting a poison control center or emergency services is mandated if overdose is suspected or if serious symptoms occur.

Therapeutic Uses of Dexavetaderm

What Dexavetaderm Treats: Main Uses and Benefits

This combination is commonly used in clinical settings where supportive management of significant localized inflammation and a bacterial presence is considered relevant. This application involves therapeutic domains where both symptoms related to inflammatory states and microbial factors are present.

The medication is generally applied in conditions characterized by periods of heightened symptoms in two main therapeutic areas. This includes steroid-responsive inflammatory ocular conditions of the anterior segment (like conjunctiva and cornea), and inflammatory bacterial skin infections (dermatoses). It is primarily relevant for managing symptom clusters that may become intense or disruptive, such as redness, swelling, and persistent itching or discomfort.

“The primary goal is to provide supportive relief during difficult episodes by easing the overall symptom load.”

This dual-action preparation supports improved comfort during symptomatic periods by assisting with the management of the inflammatory and bacterial symptom clusters. It assists with maintaining functional stability when localized symptoms interfere with routine activities.


Quick Fact Block

Quick Fact: Support for Dual Symptom Clusters Description
Primary Focus Conditions involving symptoms related to inflammatory and microbial states.
Symptomatic Relief Easing redness, swelling, itching, and localized discomfort.
Clinical Scenario Relevant when short-term symptomatic assistance may be appropriate for acute episodes.

Regulatory References

  1. DailyMed NIH listing for the combination

Eligibility and Restrictions for Use

This section outlines the official eligibility and non-eligibility requirements for Dexavetaderm (dexamethasone) as defined by authoritative government regulatory agencies.


Populations for whom use is Contraindicated

Official labeling prohibits the use of this medicine in the following populations and conditions:

  • Patients with a known hypersensitivity or allergy to dexamethasone or any component of the product.
  • Individuals with systemic fungal infections.
  • Patients receiving immunosuppressive doses who are scheduled to receive live or live attenuated vaccines.

Populations Requiring Restricted or Conditional Use

Use of Dexavetaderm requires caution and close monitoring in patients with certain pre-existing conditions, as documented in official regulatory warnings:

  • Gastrointestinal Conditions: Individuals with active or latent peptic ulcers, diverticulitis, or recent intestinal surgery (due to increased risk of perforation).
  • Infections: Patients with active or latent tuberculosis, untreated bacterial, viral, or parasitic infections (e.g., amebiasis), or ocular herpes simplex (due to the risk of infection exacerbation).
  • Chronic Diseases: Caution is necessary for patients with congestive heart failure, hypertension, renal insufficiency, diabetes mellitus, or osteoporosis.

Age and Reproductive Status Eligibility

  • Pediatric Patients: Use may be limited due to the documented risk of growth suppression in children, requiring careful risk-benefit evaluation.
  • Pregnancy: The use is conditional, as the benefit must outweigh the potential hazard to the fetus. Infants born to mothers exposed to substantial doses must be observed for signs of hypoadrenalism.
  • Breastfeeding: A decision to discontinue the drug or discontinue nursing must be made due to the potential for serious adverse reactions in nursing infants.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes the officially documented interaction patterns for the Dexamethasone and Neomycin combination product as stipulated in government regulatory documents. These interactions primarily address the potential for low-level systemic absorption from topical use, which is a key regulatory concern.

Pharmacodynamic Interaction Risks

The Neomycin component carries a regulatory caution regarding use with other medicines that are known to be neurotoxic, ototoxic, or nephrotoxic. Co-administration with agents in these categories should be avoided. This restriction is necessary because combining the product with other systemic or topical drugs having these toxicity profiles may lead to a pharmacodynamic additive effect, increasing the overall risk for toxicity.

Pharmacokinetic and Timing Constraints

The Dexamethasone component is subject to a pharmacokinetic interaction when co-administered with strong CYP3A4 inhibitors. These inhibitors can reduce the clearance of Dexamethasone, potentially leading to increased systemic exposure. Furthermore, a mandatory procedural rule requires a minimum of 5 minutes separation between the administration of this product and any other ophthalmic or otic medicinal product. No clinically relevant interactions with food, alcohol, or herbal products are documented in the official labeling.

Population-Specific Considerations

Interaction risks related to the systemic absorption of Neomycin are noted as potentially higher in specific populations. Patients of advanced age, individuals experiencing dehydration, or those with impaired renal function are recognized as having a greater risk of Neomycin-related toxicity following administration.

Mechanism of Action

Dexavetaderm contains two active components: Dexamethasone acetate and Neomycin sulfate. Dexamethasone acetate, a synthetic glucocorticoid, acts as an agonist at the intracellular Glucocorticoid Receptor (GR). Upon binding, the ligand-receptor complex translocates to the cell nucleus, where it binds to specific glucocorticoid response elements (GREs) on the genome. This genomic mechanism primarily modulates gene transcription, resulting in the upregulation of anti-inflammatory proteins, such as Lipocortin-1 (Annexin A1), which inhibits Phospholipase A2. This blockade prevents the release of arachidonic acid and subsequently the biosynthesis of pro-inflammatory eicosanoids, including prostaglandins and leukotrienes. Simultaneously, the complex downregulates the transcription of genes encoding pro-inflammatory mediators, such as various cytokines and chemokines, and inhibits the activity of transcription factors like NF-kappaB. System-level physiological consequences include generalized immunosuppression and vascular permeability reduction at the site of exposure. Neomycin sulfate, an aminoglycoside antibiotic, exerts its effect by binding irreversibly to the 30S subunit of the prokaryotic ribosome, interfering with the initiation and elongation steps of bacterial protein synthesis. This interaction leads to the production of faulty or non-functional bacterial proteins, causing disruption of cellular structure and function.

Dosage and Administration Information

The administration of Dexavetaderm is strictly limited to topical routes, primarily utilizing ophthalmic (eye) and otic (ear) forms, and the product is not intended for injection or oral ingestion. Dosage and frequency follow a pattern linked directly to the severity of the localized condition.

For mild ocular inflammation, the standard pattern involves instilling one to two drops of the suspension or applying a small ribbon of ointment (approximately a 1/2 inch ribbon) multiple times daily. In cases of severe inflammation, the regimen may commence at a high frequency, such as application hourly during waking hours, and is then systematically reduced.

Treatment is intended to be short-term, typically limited to a maximum of 10 days, and a critical principle of use involves tapering the dose frequency toward the end of the course rather than resorting to abrupt discontinuation. The ophthalmic suspension requires the container to be shaken well before each application to ensure uniform dosing.

Specific instructions for proper administration include ensuring the dropper or tube tip does not touch the eye or any surface to prevent contamination. Furthermore, if other eye products are used concurrently, an interval of at least 5 minutes must separate the applications. Dosage adjustment is generally not required for older adults or individuals with renal or hepatic impairment due to the drug’s low systemic absorption profile.

Recent Clinical Evidence

Dexavetaderm: Recent Clinical Evidence

This section details the types of studies conducted for this combination medication. The findings describe group patterns observed in research, highlighting what is known and what is still uncertain, but do not provide individual predictions.

Evidence Base for Steroid-Responsive Ocular Conditions

The evidence structure for use in conditions involving inflammation and bacterial infection in the anterior segment of the eye relies on short-term Randomized Controlled Trials (RCTs) and comparative clinical studies. These investigations examined patient groups, primarily adults following procedures such as cataract surgery. Regulatory reviews describe the evidence structure that was based on controlled trials measuring outcomes related to inflammatory states (e.g., cell presence in the eye's anterior chamber) and drug concentration at the target site. Long-term effects are not fully established; the research base is heavily focused on short-term application, with limited insight beyond the typical 7-to-10-day study duration.

Research Structure for Acute Otitis Externa (AOE)

The evidence for use in conditions involving the external ear canal relies on systematic reviews and pooled analyses of various clinical trials. Research was evaluated in both adult and pediatric patients diagnosed with acute external ear canal infection. Studies monitored outcomes related to acute changes, such as pain levels and the presence of discharge. Analyses of the clinical data describe the short-term patterns observed in local signs and symptoms during the limited treatment period. The evidence is restricted to a short treatment window (typically a maximum of 10 days), and data characterizing long-term outcomes are limited.

What Remains Under Research and Uncertainty

A significant limitation across the research is that long-term effects are not fully established; there is limited information regarding the management of outcomes over extended periods. Follow-up durations were limited in many of the key studies. Additionally, research in pediatric populations remains limited, and results apply only to the populations and specific conditions under which they were conducted.

Key Studies & References Maxitrol (Neomycin and Polymyxin B Sulfates and Dexamethasone) Ophthalmic Suspension: DailyMed NIH Listing

Frequently Asked Questions (FAQ)

Common questions about Dexavetaderm (FAQ)


Q: Is Dexavetaderm considered a steroid?

According to the official product information, Dexavetaderm contains Dexamethasone, which is officially described as a synthetic glucocorticoid or corticosteroid. This component is responsible for the medication's anti-inflammatory properties.


Q: How long does it take for Dexavetaderm to start working?

Official information indicates that the corticosteroid component acts to quickly suppress inflammation. However, a specific time frame for noticeable symptom improvement is not typically quantified in official patient information. Improvement patterns can vary depending on the condition being treated.


Q: Is it safe to use Dexavetaderm long-term?

Regulatory documents strongly caution against prolonged or long-term continuous therapy with this medication. Extended use is officially associated with risks such as increased intraocular pressure (glaucoma), cataract formation, and adrenal suppression.


Q: Is the long-term safety profile of Dexavetaderm described in research?

Regulatory documents note that the research evidence base focuses on short-term application, and long-term effects are not fully established. Known risks, such as cataracts and glaucoma, are associated with use beyond the recommended duration, highlighting the importance of the short-term treatment limits.


Q: Is it okay for children to use Dexavetaderm?

Use in children requires careful risk evaluation due to an officially documented increased risk of systemic effects, such as growth suppression and adrenal suppression, and careful consideration of risks. For some preparations, regulatory labeling indicates it is contraindicated in children younger than 2 years of age.


Q: Is there information about Dexavetaderm use during breastfeeding?

Official documentation advises caution because systemically administered corticosteroids may appear in human milk. The potential for serious adverse reactions in nursing infants must be considered, and the use should be based on a risk-benefit evaluation.


Q: Can Dexavetaderm be used for skin rashes that are not specified?

Regulatory indications for this combination product are specific to conditions involving inflammation and bacterial risk in the eye (ophthalmic) and ear (otic). Its use for unspecified skin rashes is not within the documented indications approved by regulatory bodies.


Q: Do you need a prescription to get Dexavetaderm?

Yes, this product is available only with a prescription from a doctor, as documented in regulatory labeling. It is not available for purchase over the counter.


Q: What happens if I miss using a planned application of Dexavetaderm?

The general guidance for topical medication is to apply the missed dose as soon as it is remembered. However, if it is almost time for the next scheduled dose, it is generally advised to skip the missed dose and not apply two doses at the same time.


Q: Are there any known food or drink interactions with Dexavetaderm?

Official labeling notes that there are no clinically relevant interactions documented with food, alcohol, or herbal products that are related to the use of this medication.


Q: Can Dexavetaderm cause a burning sensation on the skin?

Localized effects, such as a transient burning or stinging sensation, are classified as common adverse reactions at the site of application. This effect is temporary.


Q: Is Dexavetaderm absorbed into the bloodstream?

The product is noted to have a low systemic absorption profile when used as directed. However, the possibility of absorption into the bloodstream exists, which is the basis for warnings about systemic side effects, especially with intensive or prolonged use.


Q: What should I do if my condition doesn't improve after using Dexavetaderm?

Official patient information states that if the condition or symptoms persist after a few days of use or become aggravated, use should be discontinued and the condition re-evaluated by a healthcare professional.


Q: Does using Dexavetaderm make you more sensitive to the sun?

One officially documented side effect includes the uncommon occurrence of photophobia (sensitivity to light) related to ocular use. General skin photosensitivity is not typically listed as a common side effect of this medication.


Q: Is there a generic version of Dexavetaderm available?

Yes, generic versions containing the same active ingredients may be available. The availability of generic products is subject to local regulatory approval and market conditions.


Q: How does Dexavetaderm differ from hydrocortisone?

Dexamethasone, one of the active ingredients, is officially classified as a potent synthetic corticosteroid. This classification indicates that it has a different strength and potency level compared to corticosteroids such as hydrocortisone.


Q: Is it normal to experience a temporary tingling after applying Dexavetaderm?

Side effects at the application site commonly include sensations such as stinging, burning, or discomfort. These feelings are generally temporary and may be perceived as tingling.


Q: Why is Dexavetaderm available in different strengths?

Different strengths are available to allow for dosage adjustment based on the severity of the localized inflammatory condition being treated, as described in administration guidelines.


Q: Can using Dexavetaderm cause stretch marks?

Stretch marks (striae) are one possible skin effect associated with chronic, long-term use of high-potency topical corticosteroids. This is one reason why the use of this product is strictly restricted to short durations.


Q: What is the difference between an ointment and a cream form of Dexavetaderm?

The difference lies in the formulation vehicle used to carry the active ingredients. For example, the ointment preparation typically uses ingredients like white petrolatum, creating a thicker base than a suspension or solution.


Q: Are there any specific lifestyle restrictions when using Dexavetaderm?

Official patient information indicates that temporary blurred vision or other visual disturbances may affect the ability to drive or operate machinery. Users should be aware of this potential effect.


Q: What happens if Dexavetaderm gets into your eyes?

Regulatory guidance related to accidental exposure of the ear or skin form advises seeking attention from a healthcare professional for assessment, as special care may be necessary.


Q: What should be done if too much Dexavetaderm is applied?

Using the medication in excess of the directed dose or frequency may lead to increased systemic absorption and the risk of systemic side effects. These potential effects include conditions like adrenal suppression.


Q: Does Dexavetaderm have a risk of thinning the skin?

Prolonged use of the corticosteroid component can lead to tissue thinning, such as thinning of the cornea or sclera in ophthalmic use. Regulatory documents specifically caution against extended use for this reason.


Q: How should I store Dexavetaderm to maintain its effectiveness?

To maintain the stability and effectiveness of the product, official instructions require that it be stored at the specified controlled room temperature, protected from light, and kept in a tightly closed container. The product must not be frozen.

How should Dexavetaderm be stored and disposed of?

How to Store and Dispose of Dexavetaderm?

The storage and disposal requirements for Dexavetaderm (dexamethasone and neomycin combination) are set by regulatory authorities to maintain product stability and safety.

Storage Conditions

Condition Requirement
Temperature Store at Controlled Room Temperature (15 C to 30 C / 59 F to 86 F for suspension).
Prohibitions The product must not be frozen. Some suspension forms should not be refrigerated.
Protection Must be protected from light and stored in the container kept tightly closed.

Stability and Disposal

The container must be stored out of the sight and reach of children.

Post-Opening Stability: The ophthalmic suspension must be discarded 28 days after first opening to maintain sterility, and any unused medication should be discarded after the treatment course.

Disposal Rule: Unused or expired Dexavetaderm must be disposed of in accordance with local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dexavetaderm found in:

A-Z Index: